Competition watchdog probes claims of profiteering by US drugmaker in country where tuberculosis is biggest killer
South Africa’s Competition Commission will investigate the American drugmaker Johnson & Johnson for the high price it has been charging for the tuberculosis medicine bedaquiline, as well as for extending its 20-year patent until 2027 to block cheaper generics from entering the country.
The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF). The commission investigates matters when it has reasonable suspicion of exploitative or unethical behaviour.
This story was produced by the Bhekisisa Centre for Health Journalism. Readers can sign up here for the centre’s newsletter
